Bioavailability, DNA and Licensing - Clinical Research Informer

Search:

DAY

WEEK

MONTH

YEAR

Select your country:
Sign up | Log in

Bioavailability

DNA

Licensing

Ribometrix and Genentech Partner in Potential $1 Billion+ RNA Deal

The Pharma Data

JANUARY 5, 2021

So therapeutics that focus on RNA are designed to stop the DNA from coding for disease-causing proteins. They indicate that the potential benefits over current protein and RNA-based approaches are “potency, selectivity, oral bioavailability, tissue distribution and central nervous system penetration.”.

RNA

RNA Protein Bioavailability DNA

PharmaEngine, Inc. and Sentinel Oncology Limited Enter into an Exclusive Collaboration and License Agreement for SOL-578, a Chk1 inhibitor

The Pharma Data

DECEMBER 3, 2020

TWO: 4162) announced today that it has entered into a Collaboration and License Agreement with UK-based Sentinel Oncology Limited for advancing the new drug development of SOL-578 , a Checkpoint Kinase 1 (Chk1) inhibitor, under which PharmaEngine will fund the IND enabling studies for SOL-578. TAIPEI , Dec.

Licensing

Licensing Licensing Bioavailability DNA

Webinars

Bridging Innovation & Patient Care: The Growing Role of AI

MORE WEBINARS

Ribometrix and Genentech Partner in Potential $1 Billion+ RNA Deal

PharmaEngine, Inc. and Sentinel Oncology Limited Enter into an Exclusive Collaboration and License Agreement for SOL-578, a Chk1 inhibitor

Webinars

Stay Connected